Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

NCT00422890 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT00422890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00422890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
Lead sponsor
Technische Universität Dresden
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
Not reported
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome, myeloid leukemia